Rates of p16 (MTS1) mutations in primary tumors with 9p loss

Journal Article · Fri Jul 15 04:00:00 EDT 1994 · Science (Washington, D.C.); (United States)

DOI:https://doi.org/10.1126/science.8023167· OSTI ID:6821929

Cairns, P; Mao, L; Merlo, A; Lee, D J; Schwab, D; Eby, Y; Tokino, K; Riet, P van der; Blaugrund, J E; Sidransky, D ^[1]

---

1. Johns Hopkins Univ. School of Medicine, Baltimore, MD (United States)

Chromosomal loss at 9p21-22 has been implicated in the genesis of different types of primary tumors. The gene p16[sup INK4], an inhibitor of activated cyclin D-cdk4 complexes, recently emerged as a candidate tumor suppressor gene when it was localized to 9p21. The authors selected 75 primary tumors that displayed alleleic loss of the region. They then amplified exons 1 and 2, cloned the amplified products, and sequenced p16 from pooled clones. They conclude from the results of sequencing that p16 is not the primary target of 9p21-22 loss in a large number of nonmelanoma primary tumors. 14 refs., 1 fig., 1 tab.

• OSTI ID: 6821929
• Journal Information: Science (Washington, D.C.); (United States), Journal Name: Science (Washington, D.C.); (United States) Vol. 265:5170; ISSN SCIEAS; ISSN 0036-8075
• Country of Publication: United States
• Language: English

Related Subjects

550400* -- Genetics
59 BASIC BIOLOGICAL SCIENCES
CHROMOSOMAL ABERRATIONS
CHROMOSOMES
DISEASES
GENE MUTATIONS
HUMAN CHROMOSOME 9
HUMAN CHROMOSOMES
MUTATIONS
NEOPLASMS